Management of advanced prostate cancer after first-line chemotherapy.

Détails

ID Serval
serval:BIB_DA74BAD0A9E9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Management of advanced prostate cancer after first-line chemotherapy.
Périodique
Journal of clinical oncology
Auteur(s)
Berthold D.R., Sternberg C.N., Tannock I.F.
ISSN
0732-183X (Print)
ISSN-L
0732-183X
Statut éditorial
Publié
Date de publication
10/11/2005
Peer-reviewed
Oui
Volume
23
Numéro
32
Pages
8247-8252
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Hormone refractory prostate cancer (HRPC) causes substantial morbidity and mortality. There are increasing options for both first- and second-line therapy in the palliative treatment of patients with HRPC. Medications to control symptoms should first be optimized in patients with late-stage disease, and radiotherapy applied to dominant painful bone lesions. Docetaxel, mitoxantrone, satraplatin, and ixabepilone are active chemotherapeutic agents in the first- and/or second-line setting for patients with HRPC, and this may be true also of older drugs such as oral cyclophosphamide and vinorelbine. Radioisotopes such as strontium and samarium are useful for treatment of more generalized bone pain. Third-line hormonal maneuvers including glucocorticoids, ketoconazole, and estrogens can lead to further palliation in some patients, and there are provocative data that chemotherapy might restore hormonal sensitivity in a subset of patients.

Mots-clé
Antineoplastic Agents/classification, Antineoplastic Agents/therapeutic use, Disease Management, Humans, Male, Prostatic Neoplasms/drug therapy, Radiopharmaceuticals/classification, Radiopharmaceuticals/therapeutic use
Pubmed
Création de la notice
01/12/2016 0:36
Dernière modification de la notice
03/03/2018 21:54
Données d'usage